Home > Press > Paper Published on Keystone Nano’s Ceramide Nanoliposome Program
 |
Abstract:
Keystone Nano is pleased to announce the publication of a manuscript describing the preclinical development of the company’s lead product, the Ceramide Nanoliposome (CNL). This product is designed to more effectively treat cancer by providing selectively killing cancer cells without harming normal cells. The paper was published in June 2015 issue of Biological Chemistry and authored by Dr. Mylisa Parette, Keystone Nano’s Research Manager, Dr. Mark Kester, Keystone Nano’s Chief Medical Officer, Ms. Jocelyn Bassler, Keystone Nano Research Chemist, Dr. Carly Carter, Keystone Research Team Leader and Mr. Jeff Davidson, Keystone Nano’s CEO. Also contributing was Dr. Todd Fox of the University of Virginia.
Paper Published on Keystone Nano’s Ceramide Nanoliposome Program
State College, PA | Posted on June 11th, 2015Keystone Nano is currently compiling an Investigational New Drug filing on the Ceramide Nanoliposome for review by the US Food and Drug Administration. The company anticipates that the initial clinical trial will treat patients with a range of cancers. After this initial testing is complete, the company anticipates enrolling in clinical testing patients with Liver Cancer or other difficult to treat cancers.
####
About Keystone Nano
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.
For more information about Keystone Nano, visit our website keystonenano.com or follow us on twitter @keystonenano.
For more information, please click here
Contacts:
Jeff Davidson
CEO
814-466-5080
Dr. Mylisa Parette
Research Manager
814-237-4657
Copyright © Keystone Nano
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
MXene nanomaterials enter a new dimension Multilayer nanomaterial: MXene flakes created at Drexel University show new promise as 1D scrolls January 30th, 2026
Cancer
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
Govt.-Legislation/Regulation/Funding/Policy
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||